Hepatitis C and Merck [Merck & Co., Inc., Gilead Sciences, Inc.]

Share This Article
May 6, 2014 2:49pm NYSE:FDL NYSE:IHE

drugsHepatitis C news is all over the headlines. That’s because the Hep C market is huge – $100 billion huge. And while Gilead Sciences, Inc.(NASDAQ:GILD) has been grabbing all the headlines in that area, Merck & Co., Inc.(NYSE:MRK) is right on


its heels.

This is shaping up to be a two-horse race for the best and most affordable one-pill-a-day regimen to treat what is a horrible disease that affects 2.7 million people in the U.S. alone.

Gilead is expected to take the lion’s share of this market, 60% to 75%. That means there is 25% to 40% of the market up for grabs. This is where Merck expects to make its money.

The other players here are Bristol-Myers Squibb Co(NYSE:BMY) and AbbVie Inc(NYSE:ABBV), but their systems require multiple drugs and pills. The market sees that as a negative.

And despite the lower market share from the Hep C race, Merck has lots of other reasons to own it.

It has initiated what has been described as an aggressive two-year restructuring plan. It also has several skin cancer drugs in the pipeline, as well as a much broader and stronger overall pipeline than Gilead. And a 3.1% dividend that will work very well while investors wait for the numbers to roll in on the Hep C situation.

The stock is trading slightly below the market at about 15.5 times 2015 earnings. Gilead is at about 16 times.

The dividend and its pipeline put it over the top for me. Take a look at Merck.

by Steve McDonald, Bond Strategist

Investment U provides cutting-edge research and strategic financial recommendations for all levels of investors through its morning publication Investment U Daily and its related publications.


7 Best ETFs for the NEXT Bull Market

Read Next



Free Investing Ideas Newsletter!

Join over 70,000 investors who get the latest insights and top rated picks from our free investment newsletter.

Most Popular



7 Best ETFs for the NEXT Bull Market

Explore More from ETFDailyNews.com

Free Investment Newsletter

Join over 70,000 investors who get the latest insights and top rated picks from our free investment newsletter.

ETFDailyNews.com respects your privacy.

Best ETFs

We've rated and ranked nearly 2,000 ETFs and ETNs using our proprietary SMART Grade system.

View Top Rated ETFs

Best Categories

We've ranked dozens of ETF categories based on relative performance.

Best ETF Categories